Trials / Completed
CompletedNCT04653818
HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Alexandria University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no rise or even decrease in HCC recurrence. Most of these studies were retrospective and some were non-randomized prospective studies. Here investigators aim to perform a randomized controlled trial to study this issue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Velpatasvir/Sofosbuvir | sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant. |
Timeline
- Start date
- 2020-10-05
- Primary completion
- 2022-10-24
- Completion
- 2022-10-24
- First posted
- 2020-12-04
- Last updated
- 2023-04-04
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04653818. Inclusion in this directory is not an endorsement.